Godavari Drugs (530317)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Positive earnings with a P/E of 16.72, not excessively expensive despite the decline
• Book value of ₹51.81 provides a tangible asset base, with P/B at 1.97
• ROE of 8.86% and ROCE of 10.10% show the business is still generating positive returns
• Small-cap pharma niche could offer recovery optionality if operations stabilize

Concerns

• Sales and profit both fell roughly 25%, showing serious operational deterioration
• Piotroski F-Score of 3/9 indicates weak financial health and possible distress
• Latest quarter net profit of only ₹1 crore on ₹22 crore sales means very thin margins
• No dividend yield, so shareholders receive no income while waiting for a turnaround

AI Analysis

When I look at Godavari Drugs, I see a small pharmaceutical business selling at ₹102.10 with a market cap of just ₹79 crore. The first question I always ask is: what am I getting for my money? The book value is ₹51.81, so I am paying nearly twice the net assets. That is not a Graham-style margin of safety. Returns on capital are modest—ROE is only 8.86% and ROCE is 10.10%. That tells me this is not a wonderful business with pricing power; it is an average capital user. The recent results are worse. Sales have fallen by 24.94% and profits by 25.97%. The latest quarter shows ₹22 crore of sales and only ₹1 crore of net profit—a razor-thin margin. The Piotroski F-Score of 3 out of 9 is a serious warning sign. It suggests deteriorating financial health, not improving fundamentals. There is also no dividend, so I cannot earn anything while I wait for a recovery. In the Buffett framework, I would rather pay a fair price for a wonderful business than a cheap price for a troubled one. Here, the P/E is 16.72 with negative growth. That is not bargain territory. The 52-week range of ₹69.70 to ₹134.50 shows the market has already repriced the stock downward. Could this become a turnaround? Possibly. But I need evidence, not hope. I want to see sales stabilise, margins widen, and returns on capital improve before I take a position. For now, this belongs on the watchlist, not in a value portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer